Repligen Beats Earnings Estimates in Third Quarter

The Waltham-based life sciences firm reported $209.3 million in revenue during the third quarter.

Updated on Oct. 27, 2026 in Corporate Finance

Isometric editorial illustration of a glass laboratory centrifugal filter component, representing life sciences industry operations. — Repligen Corp. reported $209.3 million in third-quarter revenue, exceeding analyst expectations, though the company recorded a $38.4 million net loss. AI Illustration. Upload story photo >

Live Poll

Does meeting earnings expectations make you more confident in your personal investment plans?

Repligen Corp. posted $209.3 million in revenue for the third quarter of 2026, surpassing analyst expectations of $206.6 million. Despite this performance, the company reported a net loss of $38.4 million for the period.

Why it matters

The company managed to outperform Wall Street projections for both revenue and earnings, suggesting operational resilience. This financial update provides investors with a clearer picture of the firm's growth trajectory and its ability to navigate current market conditions.

Repligen reported adjusted earnings of 53 cents per share, exceeding the 46-cent estimate from Zacks Investment Research analysts. The firm also generated $209.3 million in revenue, beating the anticipated $206.6 million.

The players

Repligen Corp.

Headquartered in Waltham, this life sciences company specializes in the development and manufacturing of bioprocessing technologies.

The details

The reported $38.4 million net loss equates to 68 cents per share for the third quarter. These results were calculated after adjusting for specific asset impairment costs and amortization expenses.

Repligen reported its third-quarter financial results on Tuesday, October 27, 2026.
The financial data covers the performance period of Q3 2026.

Market Dynamics

Repligen's presentation of adjusted earnings reflects the standardized practice of using non-GAAP measures to provide transparency in line with the SEC's Regulation G. This approach helps the firm articulate its core operational success against broader macroeconomic and industry-specific headwinds.

Retail investors should note the company's full-year earnings guidance, which is projected to fall between $2.05 and $2.09 per share. These figures provide a benchmark for assessing the firm's future value following the third-quarter loss.

The takeaway

Repligen successfully outperformed analyst expectations in revenue and earnings during the third quarter. Investors should monitor whether the company achieves its projected full-year earnings range of $2.05 to $2.09 per share.